ISSN: 1098-3015

Journal Home

Journal Guideline

Value in Health Q1 Unclaimed

Elsevier Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Value in Health is a journal indexed in SJR in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health with an H index of 132. It has an SJR impact factor of 1,507 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,507.

Value in Health focuses its scope in these topics and keywords: health, comparison, metaanalysis, multiple, patients, based, review, hemodialysis, care, costeffectiveness, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Health Policy (Q1) Medicine (miscellaneous) (Q1) Public Health, Environmental and Occupational Health (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,507

SJR Impact factor

132

H Index

224

Total Docs (Last Year)

658

Total Docs (3 years)

9381

Total Refs

2479

Total Cites (3 years)

592

Citable Docs (3 years)

3.7

Cites/Doc (2 years)

41.88

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: A Cost-Utility Analysis in Spain

ISPOR Inaugural European Conference: An Overview

Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis

LONG TERM COMPLIANCE WITH ANTIHYPERTENSIVE DRUG THERAPY IN A MANAGED CARE ORGANIZATION

HP1: ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)

The Reliability and Validity of the Impact on Lifestyle Questionnaire in Patients with Acromegaly

HP2: THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS

HP3: INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS: EVALUATION OF 30 MONTHS OF EXPERIENCE

RS1: OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA: A COMPARISON OF SYMPTOM-FREE TIME AND MULTI-ATTRIBUTE SCALE

Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version

HP4: ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES: A COST-UTILITY ANALYSIS OF ORLISTAT AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY IN ADULTS

RS2: USING SELF-ADMINISTERED DIRECT TTO QUESTIONS TO ELICIT UTILITY VALUES FOR ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE

SHOW MORE ARTICLES

RS4: A MODEL-BASED EVALUATION OF INHALED STEROIDS IN MILD-TO-MODERATE ASTHMA

Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries

PCV26: CARING FOR HYPERTENSION ON INITIATION: COSTS AND EFFECTIVENESS (CHOICE). DESIGN AND RATIONALE OF A NATURALISTIC STUDY

Modeling the Efficiency of Reaching a Target Intermediate End Point: A Case Study in Type 2 Diabetes in the United States

PCV27: A PHARMACOECONOMIC MODEL TO EVALUATE TREATMENT OPTIONS FOR DVT PHARMACOPROPHYLAXIS

PCV28: CHOLESTEROL REDUCTION SUCCESS RATES AND RESOURCE UTILIZATION BY GENDER

PCV30: COST-EFFECTIVENESS MODEL OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION

PCV31: CLOSURE OF ATRIAL SEPTAL DEFECT: MEDICO-ECONOMIC ARGUMENTS TO CHOOSE BETWEEN INVASIVE SURGERY AND PERCUTANEOUS TECHNIQUE USING SEPTAL OCCLUDER

PCV32: STRATEGIES FOR IMPROVING COMPLIANCE WITH HMG-COA REDUCTASE INHIBITORS

PCV34: DECISION ANALYSIS MODEL OF ABCIXIMAB, EPTIFIBATIDE OR STANDARD THERAPY IN ELECTIVE STENT PLACEMENT: A CANADIAN PERSPECTIVE

PCV35: COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY: DO THE RESULTS HELP THE DECISION-MAKING PROCESS?

PCV36: EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATA